Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

By Jonathan Block, Associate Editor and Elizabeth S. Eaton, Staff Writer | Oct 24, 2019 | 12:20 AM GMT

Editor's note: Updated on Oct 24, 2019 at 12:43 AM GMT

bluebird bio Inc. (NASDAQ:BLUE) Chief Strategy Officer Jeffrey Walsh will step down, effective Jan. 6, 2020. The gene therapy company said CFO Chip Baird and CBO Joanne